Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

Merck & Co. Inc. closed 41.34% below its 52-week high of $134.63, which the company achieved on June 25th.

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against cancer-causing HPV in China, which previously powered Merck’s growth.

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

The stock's rise snapped a three-day losing streak.

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck & Company (MRK – Research Report) received a Hold rating and an $85.00 price target from Cantor Fitzgerald analyst Carter Gould ...

We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look ...

Merck, Black Hills, and Virtus Investment Partners are good choices for investors seeking reliable passive income. Their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...